1. Soluble expression and enzymatic activity evaluation of protease from reticuloendotheliosis virus.
- Author
-
Hu F, Zhao Y, Qi X, Cui H, Gao Y, Gao H, Liu C, Wang Y, Zhang Y, Li K, Wang X, and Wang Y
- Subjects
- Escherichia coli genetics, Mutation, Peptide Hydrolases chemistry, Peptide Hydrolases genetics, Peptide Hydrolases isolation & purification, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins isolation & purification, Reticuloendotheliosis virus genetics, Viral Proteins chemistry, Viral Proteins genetics, Viral Proteins isolation & purification, Peptide Hydrolases metabolism, Recombinant Proteins metabolism, Reticuloendotheliosis virus enzymology, Viral Proteins metabolism
- Abstract
The protease (PR) encoded by most retroviruses is deeply involved in the lifecycle and infection process of retroviruses by possessing the specificity necessary to correctly cleave the viral polyproteins and host cell proteins. However, as an important representative of avian retroviruses, the enzymatic properties of PR from reticuloendotheliosis virus (REV) have not been clearly documented. The recombinant PR, its mutant fused with a His-tag, and its substrate p18-p30 fused with a GST-tag were expressed in the Escherichia coli system as soluble enzymes. The soluble PR and p18-p30 were purified using Ni-NTA His Bind Resin and Glutathione Sepharose 4B, respectively. The enzymatic activity of PR was analyzed using the substrate of p18-p30. The expressed prokaryotic protease has enzyme activity that is dependent on such conditions as temperature, pH, and ions, and its activity can be inhibited by caspase inhibitor and the divalent metal ions Ca(2+) and Ni(2+). In addition, the key role of the residue Thr (amino acids 28) for the enzymatic activity of PR was identified. Furthermore, the caspase inhibitor Z-VAD-FMK was confirmed to inhibit the PR enzymatic activity of REV. For the first time, the PR of REV was expressed in the soluble form, and the optimal enzymatic reaction system in vitro was developed and preliminarily used. This study provides essential tools and information for further understanding the infection mechanism of REV and for the development of antiviral drugs treating retroviruses., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF